about
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaSunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.Brain metastases from colorectal carcinoma: prognostic factors and outcome.High KLF4 level in normal tissue predicts poor survival in colorectal cancer patientsThe role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study.Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experienceUpfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastasesSalvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.Novel methods for clinical risk stratification in patients with colorectal liver metastasesAdenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis.Treatment outcome of patients with anaplastic thyroid cancer: a single center experienceWeekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors.Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal CancerEffects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.Comparison of diffusion-weighted MRI and MR volumetry in the evaluation of early treatment outcomes after preoperative chemoradiotherapy for locally advanced rectal cancer.Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity.Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancerImpact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification.Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients.A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach.A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.Quantitation and pharmacokinetics of 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) in rat plasma by liquid chromatography-tandem mass spectrometry.
P50
Q33375594-A523F0DB-EE4C-4F43-9F6A-0FF81A58CCDBQ33385981-95251D99-D5E5-4886-A7B5-2692FED52561Q33396613-7DEADDBF-26F0-422C-A243-21471191F653Q33410008-7207FE52-AFF1-4BED-BFCD-E1787CF08BDBQ33410206-3DC59807-6D68-4F42-9406-8E3300EF41B6Q33566877-582D164D-4DA6-4811-BE02-D6A0919236D9Q33577959-073EF791-D730-4B51-B618-47B686BC443EQ33990397-60DB0BFF-E136-48E8-B9A2-08B6340BDD87Q34137566-2A6A1004-F485-481C-9ED8-9C538ADD3B44Q34444374-5343EE7F-A7A5-44DA-83BD-255E39AA876CQ35206160-598935B4-D6B2-45CB-BF7E-942621FECF24Q35233550-95643EA2-63C6-4B09-AEF5-FB4A8748345FQ35429661-EFCF2F1F-D8C4-4ABB-AE5D-41E29D4779A9Q35653726-07590CB3-B486-4B35-8A62-92BF459B7C77Q35767404-F83C435A-1804-4A56-9540-A3969A93C068Q35877763-2B455601-2632-462E-A0C2-A4F2601A3259Q36106616-2339D2FA-FB52-40BB-99D4-C0412AF5910EQ36187013-CFB4D6D9-5147-4027-B816-DCF3C0360D3AQ36482470-69980BD6-FB38-43AD-A95C-1E856197A1F4Q37061363-0C552F56-E975-4FDE-AD7B-C73CBD771A3AQ37367448-97116C03-35EF-4DEB-B4BD-1DF895DD1300Q37596836-6BA91A22-EB3F-43C3-A99F-2EBAB37405BDQ37606693-5906DBB0-0DF1-4C07-A15F-9C6402C36E28Q37900551-FFE0874C-B1A0-444A-9D24-EB09B371AB53Q38410346-5568D187-27E3-41E4-AFEB-D01ADBB22AE9Q38721143-A0CE656F-464F-45FE-A3C2-10AA252639D5Q38838849-DDB1C826-E2E7-4A63-BC04-67A2C0843856Q38945020-169E06EA-D6E7-4AD1-9EC7-3238BF47AC57Q39103454-033E6208-F1B3-4044-B94A-B6D14F44B9DAQ39404486-14F6B4F6-7969-433B-8591-5D51AACD8293Q39543776-1950E32A-C7D2-40E3-A6BC-82858B728DBFQ39822963-6768241C-80B3-42FB-8EED-CEB67F7C0223Q39827658-17E088F4-910C-4CC5-9BF5-425FD657DC2DQ40100453-B035F852-A039-4C8B-824E-B3CDF79CA4E9Q41115604-8698A5A0-79BD-47B1-B209-01318CA5D8A5Q41145098-1924F730-308A-47DA-B38B-4E971763D539Q41594853-592D315C-8CB8-4896-A0AD-FE3E63935C19Q42770955-B14BEF4A-D201-4BFE-9DE1-A59F0C5EF20EQ43281047-B6C99D6C-2EFA-419C-B188-651F7E7B6FD9Q44157312-7C9BCDDA-C7BF-4432-B6BA-CA02CE55346C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sang Joon Shin
@ast
Sang Joon Shin
@en
Sang Joon Shin
@es
Sang Joon Shin
@nl
type
label
Sang Joon Shin
@ast
Sang Joon Shin
@en
Sang Joon Shin
@es
Sang Joon Shin
@nl
prefLabel
Sang Joon Shin
@ast
Sang Joon Shin
@en
Sang Joon Shin
@es
Sang Joon Shin
@nl
P106
P31
P496
0000-0001-5350-7241